Efficacy and Safety of Weekly Liposome-paclitaxel Combined with Tegafur on Metastatic Gastric Cancer

Objective To evaluate the efficacy and safety of weekly liposome- paclitaxel combination with tegafur against gastric cancer. Methods Thirty metastatic gastric cancer patients received 42-day cycle of liposome- paclitaxel on day 1，8，15，22 and tegafur on day 1 to 28. Response rate and toxicity were evaluated every cycle. Results The median number of treatment was 2 cycles (1-6 cycles). The overall response rate was 26.7%, the disease controlled rate was 80%. The median progression free survival time was 6.5 months. The median overall survival time was 13.5 months. The main treatment related toxicities were hematologic toxicity, fatigue, and gastrointestinal reaction. Grade Ⅲ-Ⅳ toxicity included neutropenia (13.3%) and fatigue (3.3%). Conclusion Combination therapy of weekly liposome-paclitaxel and tegafur is an effective and well tolerated regimen in metastatic gastric cancer.